Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 101

Similar articles for PubMed (Select 24198606)

1.

Management of benign prostatic hyperplasia with silodosin.

Yamanishi T, Mizuno T, Kamai T, Yoshida K, Sakakibara R, Uchiyama T.

Open Access J Urol. 2009 Aug 20;1:1-7. Review.

2.
3.
4.

Silodosin therapy for lower urinary tract symptoms in men with suspected benign prostatic hyperplasia: results of an international, randomized, double-blind, placebo- and active-controlled clinical trial performed in Europe.

Chapple CR, Montorsi F, Tammela TL, Wirth M, Koldewijn E, Fernández Fernández E; European Silodosin Study Group.

Eur Urol. 2011 Mar;59(3):342-52. doi: 10.1016/j.eururo.2010.10.046. Epub 2010 Nov 10.

PMID:
21109344
5.

Silodosin for the treatment of clinical benign prostatic hyperplasia: safety, efficacy, and patient acceptability.

Cho HJ, Yoo TK.

Res Rep Urol. 2014 Sep 26;6:113-9. doi: 10.2147/RRU.S41618. eCollection 2014. Review.

6.

Rapid efficacy of the highly selective alpha1A-adrenoceptor antagonist silodosin in men with signs and symptoms of benign prostatic hyperplasia: pooled results of 2 phase 3 studies.

Marks LS, Gittelman MC, Hill LA, Volinn W, Hoel G.

J Urol. 2009 Jun;181(6):2634-40. doi: 10.1016/j.juro.2009.02.034. Epub 2009 Apr 16.

PMID:
19371887
7.

Silodosin: a review of its use in the treatment of the signs and symptoms of benign prostatic hyperplasia.

Keating GM.

Drugs. 2015 Feb;75(2):207-17. doi: 10.1007/s40265-014-0344-z.

PMID:
25575983
8.

Safety and efficacy of silodosin for the treatment of benign prostatic hyperplasia.

Yoshida M, Kudoh J, Homma Y, Kawabe K.

Clin Interv Aging. 2011;6:161-72. doi: 10.2147/CIA.S13803. Epub 2011 Jun 22. Review.

9.

Efficacy of silodosin for relieving benign prostatic obstruction: prospective pressure flow study.

Matsukawa Y, Gotoh M, Komatsu T, Funahashi Y, Sassa N, Hattori R.

J Urol. 2013 Jan;189(1 Suppl):S117-21. doi: 10.1016/j.juro.2012.11.031.

PMID:
23234615
10.

Efficacy of silodosin for relieving benign prostatic obstruction: prospective pressure flow study.

Matsukawa Y, Gotoh M, Komatsu T, Funahashi Y, Sassa N, Hattori R.

J Urol. 2009 Dec;182(6):2831-5. doi: 10.1016/j.juro.2009.08.030. Epub 2009 Oct 17.

PMID:
19837428
11.

Silodosin: a selective alpha1A-adrenergic receptor antagonist for the treatment of benign prostatic hyperplasia.

Schilit S, Benzeroual KE.

Clin Ther. 2009 Nov;31(11):2489-502. doi: 10.1016/j.clinthera.2009.11.024. Review.

PMID:
20109995
12.

A meta-analysis of efficacy and safety of the new α1A-adrenoceptor-selective antagonist silodosin for treating lower urinary tract symptoms associated with BPH.

Wu YJ, Dong Q, Liu LR, Wei Q.

Prostate Cancer Prostatic Dis. 2013 Mar;16(1):79-84. doi: 10.1038/pcan.2012.36. Epub 2012 Sep 18.

PMID:
22986578
13.

Rapid efficacy of the highly selective α(1A)-adrenoceptor antagonist silodosin in men with signs and symptoms of benign prostatic hyperplasia: pooled results of 2 phase 3 studies.

Marks LS, Gittelman MC, Hill LA, Volinn W, Hoel G.

J Urol. 2013 Jan;189(1 Suppl):S122-8. doi: 10.1016/j.juro.2012.11.020.

PMID:
23234617
14.

Silodosin versus naftopidil in Japanese patients with lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized multicenter study.

Shirakawa T, Haraguchi T, Shigemura K, Morishita S, Minayoshi K, Miyazaki J, Yamada Y, Miyake H, Tanaka K, Fujisawa M.

Int J Urol. 2013 Sep;20(9):903-10. doi: 10.1111/iju.12055. Epub 2012 Dec 17.

PMID:
23252453
15.

Effect of silodosin on detrusor overactivity in the male spontaneously hypertensive rat.

Inoue S, Saito M, Tsounapi P, Dimitriadis F, Ohmasa F, Kinoshita Y, Satoh K, Takenaka A.

BJU Int. 2012 Jul;110(2 Pt 2):E118-24. doi: 10.1111/j.1464-410X.2011.10814.x. Epub 2011 Dec 7.

PMID:
22146017
16.

Urodynamic effects of silodosin, a new alpha 1A-adrenoceptor selective antagonist, for the treatment of benign prostatic hyperplasia.

Yamanishi T, Mizuno T, Tatsumiya K, Watanabe M, Kamai T, Yoshida K.

Neurourol Urodyn. 2010 Apr;29(4):558-62. doi: 10.1002/nau.20802.

PMID:
19693954
17.

Effects of silodosin, a selective α1A-adrenoceptor antagonist, on bladder blood flow and bladder function in a rat model of atherosclerosis induced chronic bladder ischemia without bladder outlet obstruction.

Goi Y, Tomiyama Y, Nomiya M, Sagawa K, Aikawa K, Yamaguchi O.

J Urol. 2013 Sep;190(3):1116-22. doi: 10.1016/j.juro.2013.03.110. Epub 2013 Mar 29.

PMID:
23545103
18.

The diagnosis and treatment of lower urinary tract symptoms due to benign prostatic hyperplasia with α-blockers: focus on silodosin.

Fonseca J, Martins da Silva C.

Clin Drug Investig. 2015 Feb;35 Suppl 1:7-18. doi: 10.1007/s40261-014-0257-3.

PMID:
25708606
19.

Age and bladder outlet obstruction are independently associated with detrusor overactivity in patients with benign prostatic hyperplasia.

Oelke M, Baard J, Wijkstra H, de la Rosette JJ, Jonas U, Höfner K.

Eur Urol. 2008 Aug;54(2):419-26. doi: 10.1016/j.eururo.2008.02.017. Epub 2008 Feb 25.

PMID:
18325657
20.

A selective alpha1A-adrenoceptor antagonist inhibits detrusor overactivity in a rat model of benign prostatic hyperplasia.

Tatemichi S, Akiyama K, Kobayashi M, Yamazaki Y, Yokoyama O, Uruno T.

J Urol. 2006 Sep;176(3):1236-41.

PMID:
16890732
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk